Sleep & GLP-1
GLP-1 weight loss can dramatically improve sleep apnea, snoring, and total sleep time — but the same drugs cause sleep disruption in 5-10% of users during dose escalations. Here is what the evidence shows.
The SURMOUNT-OSA trial (NEJM 2024) showed tirzepatide 10-15 mg weekly reduced apnea-hypopnea index (AHI) by ~50% in adults with obesity, with 43% of patients achieving disease resolution. CPAP remains first-line for severe disease; GLP-1s are adjunctive but increasingly first-choice when weight is the dominant driver.
5-10% of new GLP-1 users report sleep-onset insomnia or vivid dreams during the first 2-4 weeks of dose escalations. These typically resolve as the body adapts. Magnesium glycinate at bedtime, dose splitting (smaller injection earlier in the day), and avoiding food within 3 hours of bed help.
Better metabolic control improves restorative deep sleep. Many users report shorter sleep needs (7 hrs vs 8) once weight stabilizes. Resistance training in the late afternoon, combined with a high-protein dinner, optimizes recovery while on a calorie deficit.
About 5-8% of patients report insomnia during the first 2-4 weeks of dose escalation. It is typically self-resolving. Splitting the injection earlier in the day, avoiding heavy meals near bedtime, and trying magnesium glycinate 200-400 mg at bedtime help most patients sleep through the adjustment period.
In SURMOUNT-OSA, meaningful AHI reduction appeared by week 12 and was substantial by week 24. Patients who lost ≥20% body weight had the highest rate of disease resolution. CPAP can often be stepped down (not discontinued without a follow-up sleep study) after sustained weight loss.
Comparison includes consultation flow, formulary, and pricing.
See top-rated providers